Claims

1. A combination product comprising as pharmaceutically active ingredients at least one active ingredient component A and at least one active ingredient component B, characterized in that active ingredient component A is a direct stimulator of soluble guanylate cyclase of the formula (I)



(I),

in which

R^1 is $-NR^3C(=O)OR^4$,

R^2 is hydrogen or NH_2,

R^3 is hydrogen or $(C_1\text{-}C_4)$-alkyl,

R^4 is $(C_1\text{-}C_6)$-alkyl,

and active ingredient component B is a lipid-lowering agent.

2. The combination product as claimed in claim 1,

where

R^1 is $-NR^3C(=O)OR^4$,

R^2 is NH_2,

R^3 is methyl or ethyl,

R^4 is methyl, ethyl or isopropyl.

3. The combination product as claimed in claim 1, where the direct stimulator of soluble guanylate cyclase of the formula (I) has the following structure:



4. The combination product as claimed in any of claims 1 to 3 for the treatment of diseases.

5. The combination product as claimed in any of claims 1 to 4, characterized in that the active ingredient components A and B are administered separately from one another, in particular sequentially.

6. The combination product as claimed in any of claims 1 to 5, characterized in that the active ingredient components A and B are in the form of a functional unit, in particular in the form of a mixture, of a mix or of a blend.

7. The combination product as claimed in any of claims 1 to 6, characterized in that the active ingredient components A and B are (spatially) separate from one another, in particular in the form of a kit of parts.

8. The combination product as claimed in any of claims 1 to 7, characterized in that the lipid-lowering agent (active ingredient component B) is selected from the group of (a) HMG-CoA-reductase inhibitors; (b) squalene synthase inhibitors; (c) bile acid

absorption inhibitors (bile acid sequestrants); (d) fibric acid and its derivatives; (e) nicotinic acid and its analogs; (f) ω3-fatty acids.

9. The combination product as claimed in claim 8, characterized in that the lipid-lowering agent (active ingredient component B) is an HMG-CoA reductase inhibitor and is selected in particular from the group of statins, preferably from the group of atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, simvastatin and rosuvastatin, and their respective salts, hydrates, alcohols, esters and tautomers.

10. The combination product as claimed in claim 9, characterized in that the lipid-lowering agent (active ingredient component B) is atorvastatin or its salt, hydrate, alcoholate, ester and tautomer.

11. The combination product as claimed in claim 9, characterized in that the lipid-lowering agent (active ingredient component B) is cerivastatin or its salt, hydrate, alcoholate, ester and tautomer.

12. The use of lipid-lowering agents for increasing the efficacy of direct soluble guanylate cyclase stimulators of the formula (I) as defined in claim 1.

13. A process for producing compositions as claimed in any of claims 1 to 12, characterized in that at least one lipid-lowering agent and at least one direct soluble guanylate cyclase stimulator of the formula (I) is converted, where appropriate with conventional excipients and additives, into a suitable administration form.

14. The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments for the treatment of cardiovascular disorders.

15. The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments for the treatment of hypertension.

16. The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments for the treatment of thromboembolic disorders and ischemias.

17. The use of compositions as claimed in any of claims 1 to 12 in the production of

medicaments for the treatment of sexual dysfunction.

18. The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments for the treatment of arteriosclerosis.

19. The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments for the treatment of osteoporosis.

20. The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments having an antiinflammatory effect.

21. The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments for the treatment of central nervous system disorders.

22. The use as claimed in any of claims 14 to 21, where the compositions as claimed in any of claims 1 to 13 are employed in combination with organic nitrates or NO donors or in combination with compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP).